Why AtriCure (ATRC) Is On Investors’ Radar Today

AtriCure (ATRC) has drawn fresh attention as investors reassess the stock after a difficult stretch, with negative returns over the past month, past 3 months, year to date, and over the past year.

At a share price of $27.80, AtriCure has seen weaker short term momentum, with a 30 day share price return of a 3.77% decline and a 1 year total shareholder return of a 10.84% loss pointing to prolonged pressure.

If you are reassessing your healthcare exposure, this can be a good moment to broaden your watchlist with 35 healthcare AI stocks

With AtriCure posting a 3 year total shareholder return loss of 42.28% and trading at $27.80 against a $47.00 analyst price target, investors may ask whether this represents a reset buying opportunity or whether the market is already pricing in future growth.

Most Popular Narrative: 47.3% Undervalued

The most followed narrative pegs AtriCure’s fair value at about $52.78 per share versus the recent $27.80 close, framing the stock as materially undervalued and centering the story on future clinical and product milestones.

The successful completion of enrollment in the LeAAPS clinical trial, as well as early activation of the BoxX-NoAF study, are set to substantially increase AtriCure's total addressable market if positive outcomes lead to expanded indications for stroke prevention and preventative cardiac surgery in underserved populations, which will support future revenue and earnings growth.

Curious what powers that $52.78 fair value estimate? The narrative leans heavily on double digit revenue growth, a swing into profitability and a rich future earnings multiple. The exact mix of growth, margins and discount rate assumptions may surprise you once you see them laid out.

Result: Fair Value of $52.78 (UNDERVALUED)

However, this hinges on AtriCure holding its ground against pulsed field ablation competitors and justifying heavy R&D and trial spending if outcomes or uptake disappoint.

Another View: Cash Flows Paint A Tougher Picture

The popular narrative and analyst targets lean toward AtriCure being undervalued, but the SWS DCF model points the other way, with an estimate of future cash flow value at about $2.37 per share versus the current $27.80 price, which screens as overvalued on that measure. Which signal do you trust more: earnings potential or cash flows?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AtriCure for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mixed signals in this story leave you unsure, take a closer look at the data yourself and decide how it fits your goals. To understand what some investors already see as potential bright spots, review the 3 key rewards

Looking for more investment ideas?

Before you move on, give yourself the chance to spot opportunities that others might miss using focused stock lists built from clear, transparent criteria.

• Target potentially mispriced opportunities by scanning 51 high quality undervalued stocks that combine quality fundamentals with appealing valuations.
• Prioritise resilience by reviewing 71 resilient stocks with low risk scores designed to highlight companies with steadier risk profiles.
• Hunt for tomorrow’s potential standouts with the screener containing 23 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.